Source: International Congress 2016 – Biomarkers and phenotypes of COPD and comorbidities
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
David Lomas (London, United Kingdom), David Lomas, David Lipson, Helen Barnacle, Ruby Birk, Noushin Brealey, Chang-Qing Zhu, Maggie Tabberer. LATE-BREAKING ABSTRACT: Single inhaler triple therapy (ICS/LAMA/LABA) in patients with advanced COPD: Results of the FULFIL trial. Eur Respir J 2016; 48: Suppl. 60, 4629

Member's Comments

No comment yet.

Related content which might interest you: LATE-BREAKING ABSTRACT: Indacaterol/glycopyrronium (IND/GLY) reduces the risk of exacerbations versus salmeterol/fluticasone (SFC) in moderate-to-very severe COPD patients irrespective of prior ICS/LABA/LAMA therapy: The FLAME study Source: International Congress 2016 – Novel strategies on COPD and asthma management Year: 2016 Efficacy of indacaterol/glycopyrronium (IND/GLY) versus salmeterol/fluticasone (SFC) on exacerbations and health status in GOLD Group D COPD patients: The FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 LATE-BREAKING ABSTRACT: Exacerbation phenotype directed corticosteroid therapy of COPD: Value of blood eosinophilia (primary results) Source: International Congress 2015 – The relevance of diagnostic and monitoring tools in clinical practice Year: 2015 LATE-BREAKING ABSTRACT: Effects of a fixed dose once-daily triple drug combination in smokers and non-smokers with COPD Source: International Congress 2016 – Features and impact of comorbidities in COPD Year: 2016 LATE-BREAKING ABSTRACT: Effect of fluticasone furoate (FF)/vilanterol (VI) on the rate of COPD exacerbations in everyday clinical practice: Results of the COPD Salford lung study (SLS) Source: International Congress 2016 – Best abstracts in asthma and COPD Year: 2016 LATE-BREAKING ABSTRACT: A Phase 1b study of PUR0200, a novel tiotropium formulation, in COPD patients Source: International Congress 2015 – Emerging strategies for airway disease treatments Year: 2015 Indacaterol/glycopyrronium (IND/GLY) reduces exacerbation and improves lung function versus salmeterol/fluticasone (SFC) in patients with and without prior ICS use: The FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 TIOSPIR®: Large scale trial of tiotropium Respimat® vs HandiHaler® (HH) in patients (pts) with COPD Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013 Roflumilast added to triple therapy in severe COPD patients with frequent exacerbations: Efficacy and tolerability Source: International Congress 2014 – Markers Year: 2014 LATE-BREAKING ABSTRACT: An algorithm for the identification of clinical COPD phenotypes in daily practice Source: International Congress 2016 – COPD diagnosis and management Year: 2016 LATE-BREAKING ABSTRACT: beta-blockers are associated with a reduction in COPD exacerbations in COPDGene Source: International Congress 2014 – COPD exacerbations Year: 2014 LATE-BREAKING ABSTRACT: Glycopyrronium once-daily significantly improves lung function and health status when added to fluticasone/salmeterol in patients with COPD: The GLISTEN study Source: International Congress 2014 – Latest insights in airway diseases Year: 2014 Cardiovascular (CV) safety of indacaterol/glycopyrronium (IND/GLY) compared with salmeterol/fluticasone combination (SFC) in moderate-to-very severe COPD patients with prior exacerbations: The FLAME study Source: International Congress 2016 – Pharmacological management of COPD Year: 2016 Implications of under treatment of stable COPD (SAVING study) Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 LATE-BREAKING ABSTRACT: Oxygen titration and weaning with FreeO2 in COPD patients hospitalized for exacerbation. A randomized controlled pilot study Source: International Congress 2015 – Chronic airway disorders: miscellaneous aspects Year: 2015 QVA149 reduces COPD exacerbation rate in various subgroups of patients: The SPARK study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013 LATE-BREAKING ABSTRACT: Outcome of withdrawal of one inhaler in COPD patients received combined ICS/LABA and LAMA Source: International Congress 2014 – Latest insights in airway diseases Year: 2014 Indacaterol/glycopyrronium (IND/GLY) is more effective than salmeterol/fluticasone (SFC) in reducing exacerbations, regardless of outcome measurement utilised: Results from the FLAME study Source: International Congress 2016 – Novel insights into the treatment of COPD Year: 2016 Effect of exacerbation history and ICS use on outcomes in COPD patients from the TIOSPIR™ trial Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 Indacaterol/glycopyrronium (IND/GLY) reduces exacerbations compared with salmeterol/fluticasone (SFC) in various sub-groups from the FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016